Hepatitis C Treatment Restrictions In Spotlight After HHS Report
Executive Summary
Study finds one-third of insured adults have access to hepatitis C treatment within 360 days of the first positive test. CDC suggests treating all eligible patients without restrictions and eliminating preauthorization requirements. For state Medicaid programs, 38 states require prior authorization and 12 states have substance use restrictions.
You may also be interested in...
Hepatitis C Treatment: Most Medicare Beneficiaries Are Not Getting Authorized Generics
The Office of the Inspector General finds that large rebates for higher-cost hepatitis C drugs and lack of formulary inclusion of authorized generics may be influencing the use of higher cost treatments in Medicare.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.